Remote monitoring to see if home spirometry, oximetry, scales, and surveys help track ILD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study lasts 12 months and uses home-based tools to monitor lung function, oxygen levels, weight, and patient-reported outcomes. All participants perform weekly home spirometry, with some doing daily pulse oximetry and/or weekly weight measurements depending on assignment. Participants have in-person baseline and final visits at UCSF, with follow-up visits by Zoom at 3, 6, and 9 months, and remote assessments throughout. The goal is to identify which device combination provides feasible adherence, high retention, and complete data while enabling detection of clinically significant ILD events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age 18 or older
* English speaking
* have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for \>10% of the ILD diagnoses seen at UCSF.

Exclusion Criteria:

* Patients who are unable provide informed consent for any reason or are acutely ill.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Erica Farrand, MD — University of California, San Francisco
• Study coordinator: Erica D Farrand, MD
• Email: Erica.Farrand@ucsf.edu
• Phone: 415-476-8067

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing the diagnostic journey in interstitial lung disease

  This trial tests whether bundling core tests and coordinating appointments can speed up diagnosis for adults referred with suspected interstitial lung disease.

  Recruiting Hospital de Granollers · Granollers, Barcelona · NCT07482917

• Pulmonary Fibrosis Learning and Self-Management Program (FILIP) for patients in rehab and outpatient care

  This study will try a blended digital education and self-management program for adults with fibrotic interstitial lung disease during pulmonary rehabilitation and outpatient ILD care to see if patients find it acceptable, practical, and linked to changes in health outcomes.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern and 1 other locations · NCT07457463

• HRS-9813 for idiopathic and progressive pulmonary fibrosis

  This trial will test whether HRS-9813 capsules help adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) slow disease progression or preserve lung function.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07192939

• Evaluating inhalable Imatinib for treating pulmonary hypertension and lung fibrosis

  This study is testing a new inhalable medication called XHALIP to see if it can help people with pulmonary hypertension and lung fibrosis feel better by improving their lung health.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06917196

• Portable oxygen therapy for people with mild-to-moderate interstitial lung disease

  This study is testing whether portable oxygen therapy can help people with mild-to-moderate interstitial lung disease breathe better and feel more active during physical activities.

  Recruiting Phase 2 University of Alberta · Edmonton, Alberta · NCT06053164

• Registry for Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease

  This study is collecting information from people with idiopathic pulmonary fibrosis and other lung diseases to better understand their experiences and health over several years.

  Recruiting at 39 sites Duke University · Birmingham, Alabama and 46 other locations · NCT01915511

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.